GL-0806 is an Fc gamma receptor-preferential multimerizing core stradomer that has demonstrated impressive efficacy in the standard model of multiple sclerosis, the EAE model, with superiority in this model head-to-head against several top-selling currently marketed products. GL-0806 modulates antigen presenting cells to inhibit maturation and migration into the CNS of a variety of immune cells.
GL-7190 is a complement-preferential multimerizing core stradomer that binds C1q avidly and potently prevents and treats disease in classical pathway complement-mediated models. GL-7190 blocks opsonin binding and increases anti-inflammatory response in addition to terminating complement activation. These features distinguish GL-7190 from terminal pathway and amplification loop complement inhibitors.